

CITATION REPORT

List of articles citing

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

DOI: 10.1007/s12325-019-00986-7
Advances in Therapy, 2019, 36, 2086-2095.

Source: <https://exaly.com/paper-pdf/73069596/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
9	Early biologic intervention cost-effective in RA. <i>Pharmacoeconomics & Outcomes News</i> , 2019 , 830, 13-13	0.1	
8	Synergistic benefits of Nicotine and Thymol in alleviating experimental rheumatoid arthritis. <i>Life Sciences</i> , 2019 , 239, 117037	6.8	15
7	Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. <i>Advances in Therapy</i> , 2020 , 37, 3732-3745	4.1	3
6	Copper oxide nanoparticles from <i>Rabdosia rubescens</i> attenuates the complete Freund's adjuvant (CFA) induced rheumatoid arthritis in rats via suppressing the inflammatory proteins COX-2/PGE2. <i>Arabian Journal of Chemistry</i> , 2020 , 13, 5639-5650	5.9	11
5	Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2021 , 38, 4885-4899	4.1	0
4	Cost-Effectiveness Analyses of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Diseases in Patients With Rheumatoid Arthritis: Three Approaches with a Cohort Simulation and Real-World Data.. <i>Modern Rheumatology</i> , 2022 ,	3.3	0
3	FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis. <i>Bone Research</i> , 2022 , 10,	13.3	0
2	Successful stopping of biologic therapy for remission in children and young people with juvenile idiopathic arthritis.		0
1	Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.		0